In this issue:
Treating ASCT with high-dose chemotherapy
Refractory MM treated by ASCT – outcomes
Polyclonal immunoglobulin recovery as long term predictor-marker
Cord blood-derived natural killer cells combined with ASCT – Phase 1 study
Whole body ultra-low dose CT versus spinal MRI
Secondary analysis from Phase III APIRE
RNA polymerase I inhibition with CX-5461
Novel therapeutic pathways involving MYC
Hyperhaploidy - high-risk cytogenetic subgroup
P21-activated kinase 4 potential as a new target in MM
Please login below to download this issue (PDF)